Limitations
This study has some limitations. It is a case series report with a small
number of patients. Furthermore, the three cases didn’t experience the
washout period before the tofacitinib plus IGU was given. In addition,
lung fibrosis in the cases is mild to moderate with less than 15
fibrosis scores, so our results cannot be generalized to patients with
severe forms of RA-UIP, which can lead to respiratory failure or death.